ACCESS China Spring Roadshow Company Introduction Part 1
The ACCESS China Spring Forum will be held for two days from May 14th to 15th. We look forward to your participation and exchange.
See company introduction and meeting schedule below for details. Scan the QR code below to register and get the listening link. We look forward to your arrival!
Roadshow company introduction on the 14th
On the morning of the 14th, Overseas Innovative Drug Authorization Roadshow Special · Company Introduction
Black Diamond Therapeutics ‘ core strategies target a broad spectrum of tumor families with oncogenic mutations, with the potential to benefit large patient populations with limited treatment options. The company is advancing the development of oral therapies designed to give patients the opportunity to live longer, healthier, more active lives. Its core asset, BDTX-1535, has shown durable clinical effects in non-small cell lung cancer and additional efficacy in glioblastoma.
Black Diamond Therapeutics’ MasterKey approach targets broad families of oncogenic mutations, with the potential to benefit large patient populations with limited treatment options. The company is advancing oral therapies designed to give patients the opportunity for a longer, healthier, active life. The Lead asset BDTX-1535 shows durable clinical responses in NSCLC, with additional opportunity in GBM.
ILDONG was founded in 1941 and listed on KOSPI in 2016. As of March 26, 2024, its market value exceeded US$300 million. The company has a broad product pipeline spanning chronic disease, cancer treatment, cardiovascular, antibiotics, over-the-counter and digestive treatments. The company achieved sales of US$548 million in 2022 and spent 20% of sales on research and development, with 30 projects currently under development.
ILDONG was founded in 1941 and listed on the KOSPI in 2016. As of March 26, 2024, its market capitalization exceeds $300 M. The company has a wide range of product lines covering chronic diseases, cancer treatment, cardiovascular, antibiotics, over-the -counter drugs, and digestive therapeutics. In 2022, the company achieved sales of $548 million and allocated 20% of its sales for research and development, currently managing 30 projects.
Aptamer Sciences is a global leader in aptamers. The company provides a full range of aptamer solutions from early diagnosis to disease treatment. Insufficient diversity and biological stability in the early stage limited the commercialization process of natural nucleotide aptamers, while the introduction of modified nucleotides significantly enhanced the druggability of aptamers, laying the foundation for technology commercialization. Aptamer Sciences is working hard to build a comprehensive platform for aptamer discovery and innovative product applications.
Aptamer Sciences is a global leading company in the field of aptamers. The company provides total aptamer solutions from early diagnosis to treatment of diseases. Natural nucleoside-based aptamers in the early days had limitations in commercialization due to the lack of diversity and biostability. However , since aptamers with significantly improved druggability using modified nucleosides were introduced, the technological foundation for commercialization has been laid. Aptamer Sciences is making efforts to build an integrated platform for aptamer discovery as well as the development of innovative products for application.
Kangstem Biotech adopts a step-by-step business strategy to optimize the success rate of its global new drug development. Kangstem’s original intention is to develop stem cell treatment products for rare and incurable diseases, and is preparing to become the world’s top stem cell company. Relying on the company’s unique R&D platform, the company plans to develop second-generation drugs and become a global biopharmaceutical company.
Kangstem Biotech employs a step-by-step business strategy to optimize its success rate in developing new global medicines. Established to develop stem cell therapeutic products for rare and incurable diseases, Kangstem aims to become the world’s top stem cell company, respected by customers and markets. Leveraging the company’s R&D technology, they plan to develop next-generation medicines and be recognized as a global biopharmaceutical company.
Chimeric Therapeutics brings hope to more cancer patients by discovering, developing and commercializing cell therapies with the greatest curative potential. The company uses flexible asset optimization, innovative trial design and continuous optimization of its technology platform to find innovative cell therapies with the greatest potential to cure patients.
Chimeric Therapeutics’ mission is to bring that promise to life for more patients with cancer by discovering, developing and commercializing cell therapies with the most curative potential. The company focuses on identifying innovative cell therapies with the most curative potential for patients and drives cell therapy drug development with agile asset optimization, innovative trial design, and an unwavering focus on technical operations.
Lingtai Biotech focuses on the discovery and development of First-in-class/Best-in-class small molecule innovative drugs. Based on the team’s rich R&D experience and differentiation strategy, the company established the target protein ubiquitination and degradation platform Nano-SPUD® for rapid screening and development of target intracellular proteins and E3 ligases, as well as target protein ubiquitination and degradation. Platform Lyso-SPUD® for screening and development of target extracellular proteins.
Leading Tac Pharma focuses on the discovery and development of First-in-class/Best-in-class small molecule innovative drug. Based on the team’s rich R&D experience and differentiation strategy, the company has established Nano-SPUD®, a target protein ubiquitination and Lyso-SPUD®, a target protein ubiquitination and degradation platform for the rapid screening and development of target intracellular proteins and E3 ligases, and Lyso-SPUD®, a target protein ubiquitination and degradation platform for the screening and development of target extracellular proteins.
INOVIO is a clinical-stage biotechnology company advancing DNA medicines to combat HPV-related diseases, cancers and infectious diseases. The company, with a recent market capitalization of $250.531 million, has two licensed Phase III drugs and more than 10 pipeline projects in Phase I, II or preclinical stages. These second-generation DNA drugs cover HPV-related diseases, immuno-oncology and infectious diseases.
INOVIO is a clinical-stage biotechnology company dedicated to progressing DNA medicines to combat HPV-related diseases, cancer, and infectious diseases. With a recent market capitalization of $250.531 million, the company possesses two out-licensed Phase 3 drug candidates and over 10 pipeline projects in Phase 1, 2, or preclinical stages. These next-generation DNA medicines encompass HPV-related diseases, immuno-oncology, and infectious diseases.
Renexxion, Inc. is a biotechnology company headquartered in the United States. The company provides Naronapride, an innovative oral medicine for patients with gastrointestinal diseases. Lead product Naronapride is a late-stage potential best-in-class candidate for upper and lower gastrointestinal tract symptoms and has high unmet medical need. Scientific research has shown that Naronapride has unique serotonin 5HT4 receptor agonist and dopamine D2 receptor antagonist properties, both of which are clinically proven targets. Naronapride is designed to minimize body absorption and is locally active within the intestinal lumen, potentially enhancing drug efficacy and safety. To date, the drug has completed four clinical Phase 2 studies and demonstrated positive data.
Renexxion, Inc. is a US based biotechnology company. The company committed to delivering innovative drugs to patients with a high unmet need in gastrointestinal disorders with its pipeline in a pill: Naronapride. The lead asset Naronapride is a late-stage, potential best- in-class drug candidate for indications in the upper and lower GI tract with high unmet medical needs. In scientific studies naronapride has demonstrated that it possesses a unique combination of both serotonin 5HT4 receptor agonistic and dopamine D2 receptor antagonistic properties, both clinically validated targets. Naronapride was designed to be minimally absorbable and locally active in the gut lumen to potentially enhance efficacy and safety. To date, four Phase-II studies have been completed and shown positive data.
Moda Biotech is the first commercial company in China and even Asia to delve deeply into the emerging field of immunometabolism to develop first-in-class original drugs for immunometabolism. The founding team of Moda Biotech has been deeply involved in the emerging scientific field of immunometabolism for many years. Its founder has been engaged in related basic biological theoretical research for nearly eight years. He has been committed to exploring the biological mechanism of mutual regulation between immune cells and nutrient metabolism, and has made breakthroughs in It has been discovered that therapeutic strategies for regulating immune system function can be achieved by regulating the metabolic activity of immune cells. This therapeutic strategy can be targeted and used to treat various chronic diseases caused by disorders of the immune and metabolic systems, including autoimmune diseases, cancer, metabolic diseases and various chronic diseases caused by aging.
META Pharmaceuticals Inc. is the first commercial company in China and Asia to develop innovative drugs in the emerging field of immunometabolism, which targets the metabolic pathways of immune cells. With a strong expertise in immunometabolism, the founders have spent years exploring the complex biological mechanisms that regulate immune cell metabolism and nutrient sensing. This rigorous research has led to a novel therapeutic strategy that modulates immune system function by manipulating the metabolic activity of immune cells. META Pharmaceuticals’ cutting-edge approach has enormous potential for treating a wide range of chronic diseases caused by immune and metabolic system disorders. These include autoimmune diseases, cancer, metabolic disorders, and various age-related chronic conditions. By harnessing the therapeutic strategy developed by the founding team, META Pharmaceuticals aims to provide effective treatments for patients suffering from these debilitating diseases.
Linnuo Pharmaceutical was established in August 2019. It has a R&D laboratory of nearly 1,000 square meters and a R&D team covering from concept to clinical practice in Zhangjiang Pharmaceutical Valley, Shanghai Free Trade Pilot Zone. We have independently developed unique patented technologies such as blood half-life extension (long-acting) and blood-brain barrier crossing, and developed orphan drugs for severe rare diseases based on relevant platform technologies, including complement-targeted antibodies and recombinant protein drugs. The R&D pipeline covers First-in-class (FIC) products targeting new targets, new mechanisms, and new indications, as well as Best-in-class (BIC) products empowered by platform technology and targeting mature targets.
Linno is dedicated to develop cutting-edge enabling technologies and novel therapeutic products to address major challenges in management of chronic human diseases. With proprietary Nano Brain-pass technology which enables blood-brain barrier-penetrating drug delivery for multiple forms of moieties, and next -generation pathway-selective complement inhibitors, Linno is working with partners to develop first- or best-of-class therapeutics, including orphan drugs for rare and devastating diseases.
ACCESS China Spring Roadshow Company Introduction Part 2
Roadshow company introduction on the 15th
On the morning of the 15th, Overseas Innovative Drug Authorization Roadshow Special · Company Introduction
Founded in 2011, CEFObio has long-standing experience and expertise in cell research and is focused on developing novel agents for cell regeneration and basic cell therapies for currently untreatable diseases. CEFObio’s most advanced clinical product at present is osteoblast differentiation cell therapy that promotes patient’s own bone regeneration, and aims to obtain the world’s first approved stem cell therapy for bone regeneration mechanism. The company’s next project will develop NK cell cancer therapies that harness the body’s own immune system and have few side effects. Following the global biotechnology trend, it is gradually developing towards cell and gene therapy.
CEFObio , founded in 2011 with the long-term research experiences and know-hows on cells, is focusing on developing the new drugs as the fundamental cell therapy agents for the cell regeneration and the incurable diseases that have been doctorless until now. CEFObio is currently conducting the clinical trials with its most advanced pipeline for the osteogenic differentiation cell therapy agent that induces the patient’s own bone regeneration and is aiming for the approval as the world’s first stem cell therapy agent to have proved the bone regeneration mechanism. For the next pipeline, the The company is developing the anti-cancer NK cell therapy agent that has almost no side effects and enables the complete cure as the cell therapy agent that utilizes the human immune system. Global biotrends are slowly moving towards the cell and gene therapies.
Cytimm Therapeutics is a clinical-stage biopharmaceutical company based in San Diego. The company is focused on developing innovative IL-2 gene therapies with first-line potential to treat cancer, neurodegenerative diseases and autoimmune diseases. Cytimm uses innovative technology to decouple the two opposite functions of IL-2 and develops two proprietary IL-2 gene therapy drugs, CTM103 and CTM201, each targeting a range of diseases: CTM103 mainly targets solid tumors, including lung cancer and melanoma. , breast cancer, ovarian cancer, pancreatic cancer, sarcoma, colon cancer and bladder cancer; CTM201 mainly targets systemic lupus erythematosus (SLE), psoriasis, ulcerative colitis (UC), atopic dermatitis, amyotrophic lateral cord Sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease.
Cytimm Therapeutics is a clinical-stage biopharmaceutical company located in San Diego. The company is focusing on the development of innovative IL-2 based therapies with First-In-Class potential for cancer, neurodegenerative and autoimmune diseases. Cytimm uses innovative technologies to decouple the two opposite functions of IL-2 and developed two proprietary IL-2 based drugs, CTM103 and CTM201, each targets a spectrum of diseases: CTM103 targets solid tumors including Lung Cancer, Melanoma, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Sarcoma, Colon Cancer, Bladder Cancer; CTM201 targets Systemic lupus erythematosus (SLE), Psoriasis, Ulcerative Colitis (UC), Atopic Dermatitis, Amyotrophic lateral sclerosis (ALS), Alzheimer’s disease, Parkinson’s disease. These two “pipeline-in-a-product” assets have the potential to make tremendous impacts, both socially and commercially.
Camurus is a Sweden-based pharmaceutical company focused on developing and commercializing innovative, long-acting medicines for the treatment of serious and chronic diseases. Based on the unique FluidCrystal® drug delivery technology and rich R&D experience, the company develops new drug products with first-class potential. Camurus’ clinical pipeline includes dependence, pain, cancer and endocrine diseases. The product pipeline is developed internally in parallel with collaborative development with international pharmaceutical companies.
Camurus is a Swedish science-led pharmaceutical company committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic diseases. New medicinal products with best-in-class potential are conceived based on the company’s proprietary FluidCrystal® drug delivery technologies and its extensive R&D expertise. Camurus’ clinical pipeline includes products for the treatment of dependence, pain, cancer and endocrine diseases, which are developed in-house and in collaboration with international pharmaceutical companies.
J2H is a synthetic drug development company that aims to provide drugs that contribute to human health. The company’s medicines focus on improving the oral absorption of drugs and leveraging systems that are closely integrated with patients to make generic medicines available for rare and difficult-to-treat diseases, infectious diseases and liver diseases, enabling physicians to provide differentiated treatment options to patients.
J2H is a developer of synthetic drugs designed to provide medicines to contribute to the health of mankind. The company’s drugs focus on the improvement of the oral absorption rate of drugs and the use of patient-linked systems to allow generic drugs for rare intractable diseases, infectious diseases and liver diseases, enabling doctors to present differentiated therapeutic alternatives to their patients.
Letech Biotech was founded in Suzhou in November 2020 by senior scientists who returned from studying in the United States. It is a biotechnology company focusing on the fields of tumor immunity and autoimmune diseases. Litecom Biotechnology utilizes its independently developed and globally original complementary bispecific antibody technology and immune granulocyte redirecting dual antibody technology to develop biomacromolecule drugs with higher safety, better clinical efficacy and global intellectual property rights. , to address unmet clinical needs. The company has so far completed proof-of-concept drug candidate molecules for six FIC projects and has submitted patent applications. In the next two years, multiple projects are expected to enter the clinical development stage.
Laticon Biopharma is a biotechnology company focusing on the fields of tumor immunotherapy and autoimmune diseases. Utilizing its independently developed and globally unique complementary bispecific antibody technology and immune cell redirection bispecific antibody technology, Laticon Biopharmaceuticals is dedicated to developing biologic macromolecule drugs with higher safety, better clinical efficacy, and global intellectual property rights to address unmet clinical needs. The company has completed the conceptual validation of candidate drug molecules for six FIC projects to date and has submitted patent applications. It is expected that multiple projects will enter clinical development stages successively in the next two years.
Founded in 2020, Qiyuan Biotech is an innovative pharmaceutical company focusing on autoimmune diseases. Through independent research and development and cooperation with strategic partners, it is committed to solving the unmet needs of patients and improving the quality of human life. The company’s globally patented Class I innovative drugs QY201, QY101, and QY211 have rapidly made progress in different clinical stages for different indications, and IND applications for multiple additional indications are about to begin. By focusing on patients’ unmet medical needs, independently developing highly differentiated molecules, and focusing on its core business, the company will strive to become a leader in the development of innovative drugs for autoimmune diseases.
E-nitiate Biopharmaceuticals is funded in 2020, which is an innovative pharmaceutical company focused on innovative drugs for autoimmune diseases, developing breakthrough drugs through independent research and development paired with strategic collaborations, dedicated to solving the unmet needs of patients and improving the quality of human life. The company’s globally patented Class I innovative drugs QY201, QY101, QY211 have been rapidly advanced to different clinical stages in different indications, and IND filings for multiple additional indications are imminent. By focusing on the unmet medical needs of patients, independently developing highly Differentiated molecules, with streamlined focus, the company strives to become a leader in the development of innovative drugs for autoimmune diseases.
Hangzhou Aomo Pharmaceutical Co., Ltd. was established in October 2000. It is a national high-tech enterprise dedicated to the research and development of innovative drugs with independent intellectual property rights. With the innovative design of drugs and the industrialized research and development of new drugs as its core competitiveness, Aomer Pharmaceuticals leverages the professional technology and management advantages of its overseas returnee team to integrate resources from all parties for the global development of new drugs, and continues to promote the development and launch of new drugs with independent intellectual property rights. Strive to make Aomo Pharmaceutical a world-class pharmaceutical innovative enterprise in the field. The company has carried out the research and development of more than 10 innovative drugs with independent intellectual property rights, all of which are urgently needed clinical products and globally developed products with broad market prospects. These drugs respectively involve application fields such as anesthesia, cardiovascular and cerebrovascular diseases, and tumors. The company has established the first and only original new drug platform AMCDx in the supramolecular field. The company’s AMCDx Chinese original new drug base platform has successfully developed an original new drug Aom0498 that has entered Phase III clinical trials. This product is the most potential new drug in China. Jiaqie’s only targeted muscle relaxant antagonist has received support from two countries’ major scientific and technological projects for “Major New Drug Creation” and is still being supported by the 2020 National “Major New Drug Creation” project.
Aomo Pharma Inc. (the US branch of Adamerck) is a biotechnology company cofounded by Ph.D. Youmao Qi and Qing Jie in 2000. Based on proprietary technology platform AMCDx, Aomo applies scientific expertise to develop and commercialize high-quality innovative drugs to meet unmet clinical needs. The company has a pipeline of more than 10 first-in-class drug candidates under development in anesthesia, cardiovascular diseases, eye diseases, neurodegenerative diseases and cancers. Adamgammadex (Aom0498) is one of all patented drug products, which is a best-in-class selective neuromuscular reversal agent. Two phase III pivotal clinical trials of adamgammadex in China have been completed and the NDA approval is expected to be received in China in 2024.
Yinuo Pharmaceutical focuses on the research and development of first-of-its-kind new drugs, focusing on immune and inflammatory pathways; it makes full use of its systems biology platform capabilities in complex disease signaling networks to propose innovative targets and intervention strategies to develop differentiated products. The pipeline that can be cooperated includes: highly selective small molecule inhibitors (Ph2 ready) for cardiac surgery-related acute kidney injury (CSA-AKI), breakthrough oral drugs for the treatment of diabetic fundus diseases (Ph2 ready), and drugs for the treatment of IBD. New co-drug compounds (Ph1), dual-target new mechanism drugs for the treatment of inflammatory skin diseases (IND), etc.
Ennovabio is aiming at immunology and metabolic complications. Leveraging the capabilities of the systems biology platform for complex disease signaling networks, innovative target and intervention strategies are proposed to develop differentiated products. Potential collaborative opportunities include highly selective small molecule inhibitors (Ph2 ready) targeting acute kidney injury associated with cardiac surgery (CSA-AKI), breakthrough oral therapy for diabetic retinopathy (Ph2 ready), novel combination compounds for treating IBD (Ph1), and dual-target novel mechanism therapy for inflammatory skin diseases (IND).
Radiopharm Theranostics aspires to be a recognized leader in the development of radiopharmaceutical formulations for diagnostic and therapeutic purposes in areas of high unmet medical need. Radiopharmaceuticals are safe, radioactive drugs that can be used as diagnostic or therapeutic tools. Only a very small amount of a safe radioactive drug is injected into the patient’s blood. The company has multiple powerful technology platforms including Nano-mAbs, pirate, PSA-mAb, AVβ6 integrin, DUNP19 and PTPµ.
Radiopharm Theranostics has the ambition to become a recognized leader in the development of radiopharmaceutical products for both diagnostic and therapeutic uses in areas of high unmet medical needs. Radiopharmaceuticals are safe radioactive drugs that can be used as diagnostic or therapeutic tools. Patients are given a very A small amount of safe radioactive medication injected into the blood stream. The company possesses powerful technological platforms including Nano-mAbs, pivalate, PSA-mAb, AVβ6 integrin, DUNP19, and PTPµ.
Kanglin Biotechnology is a national high-tech enterprise that aims to produce first-in-class and best-in-class innovative genetic drugs. Adhering to the original intention of providing good medicines for patients, Kanglin has always implemented the mission and vision of technological breakthrough-oriented and creating value for patients, and developed new medicines targeting clinical pain points. The areas targeted are mostly diseases that seriously affect human health, such as AIDS, Parkinson’s disease, hemophilia, and thalassemia. Kanglin’s strategy has achieved initial results, and its technical level has reached international leading levels in many aspects. Among them, the AIDS functional cure project has received support from major national science and technology projects and key R&D projects in Zhejiang Province. The clinical trial results of the thalassemia project have far exceeded those of other companies. Better than international counterparts.
Kanglin biotech has set itself the goal of developing first-in-class and best-in-class gene therapies. Guided by scientific innovation, their aspiration is very simple, to make good medicine for patients. The company is currently developing gene therapies for devastating diseases such as β-thalassemia, Parkinson’s disease, AIDS, hemophilia and others. Years of dedicated research and development have yielded initial results. Kanglin’s AIDS functional cure project has received support from the National Science and Technology Major Project as well as the Key Research and Development Projects of Zhejiang Province. Exploratory trials of their investigational β-thalassemia candidate have shown promising results, generating efficacy and safety data that indicates best-in-class potential.
As a pioneer in vectored gene therapy and recombinant active biotherapeutic products (LBPs), Hedu Biotech is committed to revolutionizing the future of medicine by harnessing the power of genetically engineered bacteria to solve complex diseases and promote everyday health. Headquartered in Shanghai’s Zhangjiang Medical Valley, CommBio has established an end-to-end technology platform and a strong pipeline of therapeutic candidates for metabolic and inflammatory immune diseases.
CommBio Therapeutics , a trailblazer in the field of Bacterial Vector Gene Therapy and Recombinant Live Biotherapeutic Products (LBPs), is revolutionizing the future of medicine by harnessing the power of genetically engineered bacteria to address complex diseases and promote daily health. With its headquarters in Zhangjiang Pharma Valley, Shanghai, CommBio has established end-to-end technology platform and robust pipeline of therapeutic candidates for metabolic and inflammatory immune diseases.
NeuDreamer works to alleviate the sleep challenges faced by 100 million people in the United States, ensuring that everyone can easily enjoy a restful sleep. Through this, the company hopes to pioneer strategies for early prevention and treatment of neurodegenerative diseases such as Alzheimer’s disease, and to deal with century-long obstacles to neurodegenerative diseases such as AD.
NeuDreamer is dedicated to alleviating the sleep challenges faced by one hundred million individuals in the US, ensuring that everyone can enjoy restful sleep effortlessly. Leveraging this opportunity, the company aspires to pioneer early prevention and treatment strategies for Alzheimer’s disease, confronting the century-long obstacle of AD and other neurodegenerative diseases.
ACCESS CHINA continues to support the global BD of China’s innovative drugs and specially held this “ACCESS CHINA China Transaction Cooperation Forum 2024”. We sincerely invite you to join us!
As the largest cross-border trading platform in China, the Yaotong China Forum series has been successfully held for 14 times since 2020, becoming a leading roadshow platform for biopharmaceutical and medical device companies at home and abroad to seek cooperation. BDs and senior managers from the medical field at home and abroad gather here, establishing a direct and effective communication channel for project exchanges and creating valuable opportunities for asset transactions.
contact us
Xiang Wendi
13733685995
wxiang@yafocapital.com
About YAFO Capital
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投资、融资服务、产品引进和资产孵化等。雅法在生物医药跨境授权及并购业务领域过往三年交易数量排名第一。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在伦敦、洛杉矶、东京、米兰、剑桥等地均设有分部。
Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., and London offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions in the past three years. For more information, please visit http://www.yafocapital.com
ACCESS CHINA
Event Name: ACCESS CHINA Networking & Gathering @BIO
Date & Time: June 2-6, 2024
Venue: San Diego
Content: Reception, 1X1 meetings
Participants: Pharma/Biotech senior management and BDs.
Registration Link: https://jinshuju.net/f/AqkB9m?x_field_1=BIO
BioToChina.org 